- Mereo BioPharma Group said the European Medicines Agency has granted a treatment for brittle bone disease as a priority medicine.

The disease, technically known as osteogenesis imperfecta, is a debilitating condition for which there is no current treatment approved by the U.S. Food and Drug Administration or the EMA.

Mereo announced commencement of a Phase 2b trial for treatment BPS-804 in adult patients with the condition in May 2017.

At 9:41am: [LON:MPH] Mereo Biopharma Group Ltd share price was +2.5p at 325p

Story provided by